The Ministry of health and social services (DHHS) updated its clinical practice guidelines for the treatment of HIV infection, focusing on the recently approved triple therapy becherrawy/alphaname tenofovir/emtricitabine.
The updated document has undergone schema changes starting therapy recommended for most people living with HIV:
As stated in the document, becherrawy – a new inhibitor of HIV-1 integrase. Based on the results of clinical trials, the expert group recommends the use of BIC/TAF/FTC 50/25/200 mg once per day as one of the schemes of starting therapy.
The most important news of healthcare now and in our Telegram channel @medpharm.